Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-NMMA + taxane
- Development stage
- Unknown
- Lead developer
- Houston Methodist
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
L-NMMA + taxane is a combination therapy consisting of NG-monomethyl-L-arginine (L-NMMA), a pan-nitric oxide synthase (NOS) inhibitor, and a taxane chemotherapy agent (such as docetaxel, paclitaxel, or nab-paclitaxel). This combination targets the inducible nitric oxide signaling (iNOS) pathway, which is associated with poor prognosis in triple-negative breast cancer (TNBC). The therapy works by changing the tumor microenvironment, potentially enabling immune cells to infiltrate the tumor and generate an anti-tumor inflammatory response.
- Other names
- NG-monomethyl-L-arginine + taxane
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on L-NMMA + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-NMMA + taxane.